| Targeting tumors with nanobodies for cancer imaging and therapy S Oliveira, R Heukers, J Sornkom, RJ Kok, PMPB en Henegouwen Journal of Controlled Release 172 (3), 607-617, 2013 | 235 | 2013 |
| EGFR targeted nanobody–photosensitizer conjugates for photodynamic therapy in a pre-clinical model of head and neck cancer PBAA Van Driel, MC Boonstra, MD Slooter, R Heukers, MA Stammes, ... Journal of Controlled Release 229, 93-105, 2016 | 154 | 2016 |
| Nanobody-albumin nanoparticles (NANAPs) for the delivery of a multikinase inhibitor 17864 to EGFR overexpressing tumor cells I Altintas, R Heukers, R van der Meel, M Lacombe, M Amidi, ... Journal of Controlled Release 165 (2), 110-118, 2013 | 119 | 2013 |
| Nanobody–photosensitizer conjugates for targeted photodynamic therapy R Heukers, PMPB en Henegouwen, S Oliveira Nanomedicine: Nanotechnology, Biology and Medicine 10 (7), 1441-1451, 2014 | 107 | 2014 |
| Targeting hepatocyte growth factor receptor (Met) positive tumor cells using internalizing nanobody-decorated albumin nanoparticles R Heukers, I Altintas, S Raghoenath, E De Zan, R Pepermans, ... Biomaterials 35 (1), 601-610, 2014 | 83 | 2014 |
| Endocytosis of EGFR requires its kinase activity and N-terminal transmembrane dimerization motif R Heukers, JF Vermeulen, F Fereidouni, AN Bader, J Voortman, ... Journal of cell science 126 (21), 4900-4912, 2013 | 74 | 2013 |
| Nanobody-targeted photodynamic therapy selectively kills viral GPCR-expressing glioblastoma cells TWM De Groof, V Mashayekhi, TS Fan, ND Bergkamp, J Sastre Toraño, ... Molecular pharmaceutics 16 (7), 3145-3156, 2019 | 70 | 2019 |
| EGFR and Src are involved in indole-3-carbinol-induced death and cell cycle arrest of human breast cancer cells EP Moiseeva, R Heukers, MM Manson Carcinogenesis 28 (2), 435-445, 2007 | 67 | 2007 |
| The constitutive activity of the virally encoded chemokine receptor US28 accelerates glioblastoma growth R Heukers, TS Fan, RH de Wit, JR van Senten, TWM De Groof, ... Oncogene 37 (30), 4110-4121, 2018 | 66 | 2018 |
| Heterogeneity assessment of antibody-derived therapeutics at the intact and middle-up level by low-flow sheathless capillary electrophoresis-mass spectrometry R Haselberg, T De Vijlder, R Heukers, MJ Smit, EP Romijn, GW Somsen, ... Analytica chimica acta 1044, 181-190, 2018 | 61 | 2018 |
| Nanobodies: New avenues for imaging, stabilizing and modulating GPCRs TWM De Groof, V Bobkov, R Heukers, MJ Smit Molecular and cellular endocrinology 484, 15-24, 2019 | 58 | 2019 |
| Nanobody-Fc constructs targeting chemokine receptor CXCR4 potently inhibit signaling and CXCR4-mediated HIV-entry and induce antibody effector functions V Bobkov, AM Zarca, A Van Hout, M Arimont, J Doijen, M Bialkowska, ... Biochemical pharmacology 158, 413-424, 2018 | 55 | 2018 |
| Advanced fluorescence microscopy reveals disruption of dynamic CXCR4 dimerization by subpocket-specific inverse agonists A Işbilir, J Möller, M Arimont, V Bobkov, C Perpiñá-Viciano, C Hoffmann, ... Proceedings of the National Academy of Sciences 117 (46), 29144-29154, 2020 | 54 | 2020 |
| Nanobodies detecting and modulating GPCRs outside in and inside out R Heukers, TWM De Groof, MJ Smit Current Opinion in Cell Biology 57, 115-122, 2019 | 50 | 2019 |
| CXCR4-targeting nanobodies differentially inhibit CXCR4 function and HIV entry A Van Hout, A Klarenbeek, V Bobkov, J Doijen, M Arimont, C Zhao, ... Biochemical pharmacology 158, 402-412, 2018 | 46 | 2018 |
| Inhibition of tumor growth by targeted anti-EGFR/IGF-1R nanobullets depends on efficient blocking of cell survival pathways R van der Meel, S Oliveira, I Altintas, R Heukers, EHE Pieters, ... Molecular pharmaceutics 10 (10), 3717-3727, 2013 | 42 | 2013 |
| Depleting MET-Expressing Tumor Cells by ADCC Provides a Therapeutic Advantage over Inhibiting HGF/MET Signaling Cancer Research 75 (16), 3373-3383, 2015 | 40 | 2015 |
| VHH-photosensitizer conjugates for targeted photodynamic therapy of met-overexpressing tumor cells R Heukers, V Mashayekhi, M Ramirez-Escudero, H de Haard, TC Verrips, ... Antibodies 8 (2), 26, 2019 | 35 | 2019 |
| CXCR4-specific nanobodies as potential therapeutics for WHIM syndrome RH de Wit, R Heukers, HJ Brink, A Arsova, D Maussang, P Cutolo, ... Journal of Pharmacology and Experimental Therapeutics 363 (1), 35-44, 2017 | 33 | 2017 |
| Anti-CfaE nanobodies provide broad cross-protection against major pathogenic enterotoxigenic Escherichia coli strains, with implications for vaccine design A Amcheslavsky, AL Wallace, M Ejemel, Q Li, CT McMahon, M Stoppato, ... Scientific reports 11 (1), 2751, 2021 | 27 | 2021 |
Sabrina OliveiraUtrecht UniversityGeverifieerd e-mailadres voor uu.nl
